Similar articles for PMID: 25745043

Year	Number of Results
1990	1
1991	1
1992	1
1994	1
1995	3
1996	1
1997	1
1999	1
2000	2
2001	1
2002	1
2004	1
2005	2
2007	4
2008	1
2009	2
2010	6
2011	8
2012	8
2013	14
2014	16
2015	52
2016	37
2017	48
2018	57
2019	52
2020	52
2021	36
2022	50
2023	16
2024	1

1

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Wollin L, et al. Eur Respir J. 2015 May;45(5):1434-45. doi: 10.1183/09031936.00174914. Epub 2015 Mar 5. Eur Respir J. 2015. PMID: 25745043 Free PMC article. Review.

2

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.

Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Wollin L, et al. J Pharmacol Exp Ther. 2014 May;349(2):209-20. doi: 10.1124/jpet.113.208223. Epub 2014 Feb 20. J Pharmacol Exp Ther. 2014. PMID: 24556663

3

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.

Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, Sun Q, Mandal J, Lardinois D, Lambers C, Roth M. Hostettler KE, et al. Respir Res. 2014 Dec 12;15(1):157. doi: 10.1186/s12931-014-0157-3. Respir Res. 2014. PMID: 25496490 Free PMC article.

4

The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.

Grimminger F, Günther A, Vancheri C. Grimminger F, et al. Eur Respir J. 2015 May;45(5):1426-33. doi: 10.1183/09031936.00149614. Epub 2015 Mar 5. Eur Respir J. 2015. PMID: 25745048 Free article. Review.

5

Nintedanib in the treatment of idiopathic pulmonary fibrosis.

Mazzei ME, Richeldi L, Collard HR. Mazzei ME, et al. Ther Adv Respir Dis. 2015 Jun;9(3):121-9. doi: 10.1177/1753465815579365. Epub 2015 Apr 10. Ther Adv Respir Dis. 2015. PMID: 25862013 Free article. Review.

6

Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.

Epstein Shochet G, Wollin L, Shitrit D. Epstein Shochet G, et al. Respirology. 2018 Aug;23(8):756-763. doi: 10.1111/resp.13287. Epub 2018 Mar 12. Respirology. 2018. PMID: 29532550

7

Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.

Dimitroulis IA. Dimitroulis IA. Respir Care. 2014 Sep;59(9):1450-5. doi: 10.4187/respcare.03023. Epub 2014 Apr 29. Respir Care. 2014. PMID: 24782550 Free article. Review.

8

Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.

Fukihara J, Kondoh Y. Fukihara J, et al. Expert Rev Respir Med. 2016 Dec;10(12):1247-1254. doi: 10.1080/17476348.2016.1249854. Epub 2016 Oct 31. Expert Rev Respir Med. 2016. PMID: 27744713 Review.

9

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.

Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M. Wollin L, et al. Eur Respir J. 2019 Sep 19;54(3):1900161. doi: 10.1183/13993003.00161-2019. Print 2019 Sep. Eur Respir J. 2019. PMID: 31285305 Free PMC article. Review.

10

Nintedanib in idiopathic pulmonary fibrosis.

Woodcock HV, Maher TM. Woodcock HV, et al. Drugs Today (Barc). 2015 Jun;51(6):345-56. doi: 10.1358/dot.2015.51.6.2336331. Drugs Today (Barc). 2015. PMID: 26261848 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

437 results

Results by year